Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT in T2DM and CKD
NCT03270956Phase 2Completed
- Sponsor
- ProKidney
- Start
- Apr 2018
- Primary completion
- Nov 2022
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of rilparencel in diabetic nephropathy (DN), chronic kidney disease (CKD), sponsored by ProKidney. Started Apr 2018; status: completed.
02
Drugs
rilparencel
03
Conditions
diabetic nephropathy (DN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03270956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270956.